Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.67 USD
+0.01 (0.38%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.67 USD
+0.01 (0.38%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
NASH Space in Focus as Galmed (GLMD) Posts Positive Data
by Ekta Bagri
Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.
Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%
by Zacks Equity Research
Galectin Therapeutics Inc. (GALT) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
by Zacks Equity Research
Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.
Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Galectin Therapeutics, Inc. (GALT) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Can The Uptrend Continue for Galectin Therapeutics (GALT)?
by Zacks Equity Research
Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?
by Zacks Equity Research
Edward Lifesciences Corp. (EW) is scheduled to report first-quarter 2017 earnings results after market close on Apr 25.
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) is expected to report first-quarter 2017 results on Apr 27, before the opening bell.
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
by Zacks Equity Research
We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report first-quarter 2017 financial results on Apr 18, before the opening bell.
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
by Zacks Equity Research
Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.
Can The Uptrend Continue for Galectin Therapeutics (GALT)?
by Zacks Equity Research
Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance